Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C

The cytoprotective effects of prostaglandins have been utilized in the prevention of hepatitis B virus reactivation after liver transplantation. This pilot study evaluated the effects of oral prostaglandin E2 (PGE2) in chronic viral hepatitis B and C. Twenty patients with chronic hepatitis B and 20 patients with chronic hepatitis C received 4mgday–1 PGE2 for 6 months. The lymphocyte antiviral enzyme 2’,5’‐oligoadenylate synthetase (2’,5’‐OAS) and peripheral blood monocyte procoagulant activity (PCA) were measured before, during and after the treatment. Three of 20 hepatitis B and five of 20 hepatitis C patients withdrew from the study. Eight of 17 hepatitis B patients responded: in seven of these eight patients, serum alanine aminotransferase (ALT) levels normalized; loss of viral replication was sustained in all eight patients; and seroconversion from hepatitis Be antigen (HBeAg) to hepatitis Be antibody (HBeAb) positivity occurred in seven patients over the 48‐week duration of this study. In 14 of the 15 hepatitis C patients, hepatitis C virus (HCV) RNA remained detectable and the serum ALT levels remained elevated. 2’,5’‐OAS levels and PCA values did not correlate with other markers of response to PGE2 therapy in either chronic hepatitis B or C. In summary, PGE2 was associated with sustained loss of viral replication in 47% of chronic hepatitis B patients; no beneficial effects were apparent in chronic hepatitis C.

[1]  Ally,et al.  A ONE-YEAR TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS B , 2000 .

[2]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[3]  Y. Liaw,et al.  Efficacy of thymosin α1 in patients with chronic hepatitis B: A randomized, controlled trial , 1998 .

[4]  Aril Frydén,et al.  Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C , 1998, The Lancet.

[5]  J. Koskinas,et al.  Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa‐2b for 6 or 12 months: A 4‐year follow‐up of 211 patients , 1997, Hepatology.

[6]  T. Poynard,et al.  Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration , 1996, Hepatology.

[7]  D. Häussinger,et al.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.

[8]  P. Marcellin,et al.  Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C , 1995, Hepatology.

[9]  L. Blendis,et al.  Toxic effects of intravenous and oral prostaglandin E therapy in patients with liver disease. , 1994, The American journal of medicine.

[10]  P. Greig,et al.  PROSTAGLANDIN E IN THE TREATMENT OF RECURRENT HEPATITIS B INFECTION AFTER ORTHOTOPIC LIVER TRANSPLANTATION , 1994, Transplantation.

[11]  D. Dhumeaux,et al.  Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C. , 1994, Gastroenterology.

[12]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[13]  Y. Okamoto,et al.  Prostaglandin E2 and rat liver regeneration. , 1993, Gastroenterology.

[14]  G. Davis,et al.  Significance of serum hepatitis C virus RNA levels in chronic hepatitis C , 1993, The Lancet.

[15]  G. Gasbarrini,et al.  Interferon-alpha increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon? , 1993, Journal of hepatology.

[16]  H. Thomas,et al.  Which patients with chronic hepatitis B virus infection will respond to α‐interferon therapy? A statistical analysis of predictive factors , 1989, Hepatology.

[17]  M. Abecassis,et al.  Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report. , 1989, The Journal of clinical investigation.

[18]  M. Abecassis,et al.  Treatment of primary liver graft nonfunction with prostaglandin E1. , 1989, Transplantation.

[19]  Young-In Kim,et al.  Interferon‐associated lymphocyte 2′,5′‐oligoadenylate synthetase in acute and chronic viral hepatitis , 1989, Hepatology.

[20]  T. Utsunomiya,et al.  Effects of prostaglandin E1 on posttransfusion hepatitis following surgery. , 1988, Fukuoka igaku zasshi = Hukuoka acta medica.

[21]  M. Abecassis,et al.  16, 16 Dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection. , 1987, The Journal of clinical investigation.

[22]  R. Hickman,et al.  The effect of prostaglandins, branched-chain amino acids and other drugs on the outcome of experimental acute porcine hepatic failure. , 1987, Journal of hepatology.

[23]  M. Papagni,et al.  Evaluation of the cytoprotective effect of natural and synthetic prostaglandins in CCl4-induced liver cell damage. , 1987, Advances in prostaglandin, thromboxane, and leukotriene research.

[24]  R. N. Macsween,et al.  The streaming liver: A slow, divided flow? , 1986 .

[25]  S. Kunkel,et al.  Prostaglandins as endogenous mediators of interleukin 1 production. , 1986, Journal of immunology.

[26]  T. Edgington,et al.  The Pathobiology of Viral Hepatitis and Immunologic Activation of the Coagulation Protease Network , 1984, Seminars in liver disease.

[27]  M. Goldyne,et al.  Prostaglandin E is required for the augmentation of procoagulant activity of LPS-stimulated rabbit alveolar macrophages. , 1984, Journal of immunology.

[28]  D. Giron.  Inhibition of Viral Replication in Cell Cultures Treated with Prostaglandin E1 1 , 1982, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[29]  S. Sherlock,et al.  Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. , 1981, Gastroenterology.

[30]  E. Mihich,et al.  Prostaglandin modulation of development of cell-mediated immunity in culture , 1980, Nature.

[31]  A. Robert,et al.  Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. , 1979, Gastroenterology.

[32]  A. Robert,et al.  Intestinal lesions produced by prednisolone: prevention (cytoprotection) by 16,16-dimethyl prostaglandin E2. , 1978, The American journal of physiology.

[33]  T. Merigan,et al.  Effect of vidarabine on chronic hepatitis B virus infection. , 1978, JAMA.